The role of somatostatin and dopamine D 2 receptors in endocrine tumors

Endocrine-Related Cancer

Volumn 18, Issue 6, 2011, Pages

  Gatto, Federico ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BETA ARRESTIN 1; BETA ARRESTIN 2; BIM 23A 387; BIM 23A 760; BROMOCRIPTINE; CABERGOLINE; CATECHOLAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPASTATIN; EVEROLIMUS; G PROTEIN COUPLED RECEPTOR KINASE; KI 67 ANTIGEN; MESSENGER RNA; OCTREOTIDE; PASIREOTIDE; PROTEIN KINASE C; QUINPIROLE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2A; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ACTH SECRETING ADENOMA; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOID; DRUG BINDING; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVATION; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS ADENOMA; INSULINOMA; INTERNALIZATION; LUNG CARCINOID; LUNG SMALL CELL CANCER; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PARAGANGLIOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PROLACTINOMA; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STOMACH TUMOR; THYROID MEDULLARY CARCINOMA;

DOPAMINE AGONISTS; ENDOCRINE GLAND NEOPLASMS; HUMANS; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84855940639     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0334     Document Type: Review

References (179)

1. Ameri P, Gatto F, Arvigo M, Villa G, Resmini E, Minuto F, Murialdo G & Ferone D 2007 Somatostatin receptor scintigraphy in thoracic diseases. Journal of Endocrinological Investigation 30 889-902.
2. Arnold R, Chen YJ, Costa F, Falconi M, Gross D, Grossman AB, Hyrdel R, Kos-Kudla B, Salazar R & Plockinger U 2009 ENET Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 90 227-233. (doi:10.1159/000225952)
3. Arvigo M, Gatto F, Ruscica M, Ameri P, Dozio E, Albertelli M, Culler MD, Motta M, Minuto F, Magni P et al. 2010 Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. Journal of Endocrinology 207 309-317. (doi:10.1677/JOE-10-0342)
4. Baragli A, Alturaihi H, Watt HL, Abdallah A & Kumar U 2007 Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signalling 19 2304-2316. (doi:10.1016/j.cellsig.2007.07.007)
5. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA & Klibanski A 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 91 4482-4488. (doi:10.1210/jc.2006-1245)
6. Ben-Jonathan N & Hnasko R 2001 Dopamine as a prolactin (PRL) inhibitor. Endocrine Reviews 22 724-763. (doi:10.1210/er.22.6.724)
7. Ben-Shlomo A & Melmed S 2007 Pasireotide - a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs: the Investigational Drugs Journal 10 885-895.
8. Ben-Shlomo A & Melmed S 2010 Pituitary somatostatin receptor signaling. Trends in Endocrinology and Metabolism 21 123-133. (doi:10.1016/j.tem.2009.12.003)
9. Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M & Melmed S 2009 Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. Journal of Clinical Endocrinology and Metabolism 94 4342-4350. (doi:10.1210/jc.2009-1311)
10. Berenger N, Moretti JL, Boaziz C, Vigneron N, Morere JF & Breau JL 1996 Somatostatin receptor imaging in small cell lung cancer. European Journal of Cancer 32A 1429-1431. (doi:10.1016/0959-8049(96)00078-0)
11. Bloch B, Dumartin B & Bernard V 1999 In vivo regulation of intraneuronal trafficking of G protein-coupled receptors for neurotransmitters. Trends in Pharmacological Sciences 20 315-319. (doi:10.1016/S0165-6147(99)01360- 7)
12. Bohm SK, Grady EF & Bunnett NW 1997 Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochemical Journal 322 1-18.
13. 2A in human rheumatoid synovium. Journal of Rheumatology 26 532-535.
14. de Bruin C, Feelders RA, Lamberts SW & Hofland LJ 2009a Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Reviews in Endocrine & Metabolic Disorders 10 91-102. (doi:10.1007/s11154- 008-9082-4)
15. 2 and somatostatin receptor subtype expression by glucocorticoids in vitro. Journal of Molecular Endocrinology 42 47-56. (doi:10.1677/JME-08-0110)
16. de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, van Aken MO, van der Lelij AJ, de Herder WW, Lamberts SWet al. 2009c Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. Journal of Clinical Endocrinology and Metabolism 94 1118-1124. (doi:10.1210/jc.2008-2101)
17. 2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Molecular Endocrinology 24 240-249. (doi:10.1210/me.2009- 0321)
18. Child DF, Laing I & Ganguli PC 1978 Failure of oral bromocriptine to affect hypergastrinemia in two patients with the Zollinger-Ellison syndrome. Journal of Endocrinological Investigation 1 351-353. (Pubitemid 9126278)
19. Chneiweiss H, Glowinski J & Premont J 1985 Modulation by monoamines of somatostatin-sensitive adenylate cyclase on neuronal and glial cells from the mouse brain in primary cultures. Journal of Neurochemistry 44 1825-1831. (doi:10.1111/j.1471-4159.1985.tb07175.x)
20. Cho D, Zheng M, Min C, Ma L, Kurose H, Park JH & Kim KM 2010 Agonist-induced endocytosis and receptor phosphorylation mediate resensitization of dopamine D(2) receptors. Molecular Endocrinology 24 574-586. (doi:10.1210/me.2009-0369)
21. Colao A, Filippella M, Pivonello R, Di Somma C, Faggiano A & Lombardi G 2007 Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. European Journal of Endocrinology 156 (Suppl 1) S57-S63. (doi:10.1530/eje.1.02348)
22. Colao A, Faggiano A & Pivonello R 2010 Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. Progress in Brain Research 182 281-294. (doi:10.1016/S0079-6123(10)82012-6)
23. De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, Platania M & Verzoni E 2007 Pulmonary carcinoid tumours: indolent but not benign. Oncology 73 162-168. (doi:10.1159/000127382)
24. Duet M, Patrice TB, Michel W & Liote F 2005 Plasma cell problems: case 3. Plasmacytoma mimicking a paraganglioma of the skull base: diagnostic value of somatostatin receptor scintigraphy. Journal of Clinical Oncology 23 3143-3145. (doi:10.1200/JCO.2005.06.011)
25. Duran-Prado M, Malagon MM, Gracia-Navarro F & Castano JP 2008 Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Molecular and Cellular Endocrinology 286 63-68. (doi:10.1016/j.mce.2007.12.006)
26. Duran-Prado M, Gahete MD, Martinez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-Lopez P, Leal A, Schulz S, Gracia-Navarro F et al. 2009 Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 94 2634-2643. (doi:10.1210/jc.2008-2564)
27. 5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism 95 2497-2502. (doi:10.1210/jc.2009-2247)
28. Elberg G, Hipkin RW & Schonbrunn A 2002 Homologous and heterologous regulation of somatostatin receptor 2. Molecular Endocrinology 16 2502-2514. (doi:10.1210/me.2002-0207)
29. van Essen M, Krenning EP, Bakker WH, de Herder WW, van Aken MO & Kwekkeboom DJ 2007 Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. European Journal of Nuclear Medicine and Molecular Imaging 34 1219-1227. (doi:10.1007/s00259-006-0355-4)
30. Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S et al. 2006 Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 84 196-211. (doi:10.1159/000098012)
31. Farrell WE, Clark AJ, Stewart MF, Crosby SR & White A 1992 Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines. Journal of Clinical Investigation 90 705-710. (doi:10.1172/JCI115941)
32. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Waaijers AM, de Krijger RR, Kwekkeboom DJ, Lamberts SWJ, de Herder WW & Hofland LJ 2010 Somatostatin and dopamine receptor (co-)expression in neuroendocrine tumors with ectopic ACTH production: potential targets for medical treatment. ENDO 2010, The Endocrine Society's 92nd Annual Meeting, San Diego, CA, USA. Abstract P1-649
33. Ferone D, Kwekkeboom DJ, Pivonello R, Bogers AA, Lamberts SW, van Hagen PM & Hofland LJ 2001 In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. Journal of Endocrinological Investigation 24 522-528. (Pubitemid 32691166)
34. Ferone D, Pivonello R, Van Hagen PM, Dalm VA, Lichtenauer-Kaligis EG, Waaijers M, Van Koetsveld PM, Mooy DM, Colao A, Minuto F et al. 2002 Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. American Journal of Physiology. Endocrinology and Metabolism 283 E1056-E1066. (doi:10.1152/ajpendo.00205.2001)
35. Ferone D, Arvigo M, Semino C, Jaquet P, Saveanu A, Taylor JE, Moreau JP, Culler MD, Albertelli M, Minuto F et al. 2005 Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin- dopamine molecules on cell proliferation. American Journal of Physiology. Endocrinology and Metabolism 289 E1044-E1050. (doi:10.1152/ajpendo.00209.2005)
36. Ferone D, Pivonello R, Resmini E, Boschetti M, Rebora A, Albertelli M, Albanese V, Colao A, Culler MD & Minuto F 2007a Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. European Journal of Endocrinology 156 (Suppl 1) S37-S43. (doi:10.1530/eje.1.02351)
37. Ferone D, Saveanu A, Culler MD, Arvigo M, Rebora A, Gatto F, Minuto F & Jaquet P 2007b Novel chimeric somatostatin analogs: facts and perspectives. European Journal of Endocrinology 156 (Suppl 1) S23-S28. (doi:10.1530/eje.1.02356)
38. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW & Hofland LJ 2008 Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. Journal of Clinical Endocrinology and Metabolism 93 1412-1417. (doi:10.1210/jc.2007-1358)
39. Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, Esposito D & Minuto F 2009 The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. Journal of Molecular Endocrinology 42 361-370. (doi:10.1677/JME-08-0162)
40. Ferone D, Pivonello R, Kwekkeboom DJ, Gatto F, Ameri P, Cola A, de Krijger RR, Minuto F, Lamberts SWJ, van Hagen M et al. 2011 Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: implications for the in vivo visualization during somatostatin receptor scintigraphy. Journal of Endocrinological Investigation [in press]. Florio T 2008 Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuro-endocrine tumors. Frontiers in Bioscience 13 822-840. (doi:10.2741/2722)
41. Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK, Theodoropoulou M, Culler MD et al. 2008 Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine-Related Cancer 15 583-596. (doi:10.1677/ERC-07- 0271)
42. Gagnon AW, Kallal L & Benovic JL 1998 Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta2-adrenergic receptor. Journal of Biological Chemistry 273 6976-6981. (doi:10.1074/jbc.273.12.6976)
43. Georgii-Hemming P, Stromberg T, Janson ET, Stridsberg M, Wiklund HJ & Nilsson K 1999 The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. Blood 93 1724-1731. (Pubitemid 29102501)
44. Granberg D, Sundin A, Janson ET, Oberg K, Skogseid B & Westlin JE 2003 Octreoscan in patients with bronchial carcinoid tumours. Clinical Endocrinology 59 793-799. (doi:10.1046/j.1365-2265.2003.01931.x)
45. Grant M, Collier B & Kumar U 2004 Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. Journal of Biological Chemistry 279 36179-36183. (doi:10.1074/jbc.M407310200)
46. Grant M, Alturaihi H, Jaquet P, Collier B & Kumar U 2008 Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Molecular Endocrinology 22 2278-2292. (doi:10.1210/me.2007-0334)
47. Gray JA & Roth BL 2002 Cell biology. A last GASP for GPCRs? Science 297 529-531. (doi:10.1126/science.1075453)
48. Grossrubatscher E, Veronese S, Ciaramella PD, Pugliese R, Boniardi M, De Carlis L, Torre M, Ravini M, Gambacorta M & Loli P 2008 High expression of dopamine receptor subtype 2 in a large series of neuroendocrine tumors. Cancer Biology & Therapy 7 1970-1978. (doi:10.4161/cbt.7.12.6957)
49. Grozinsky-Glasberg S, Grossman AB & Korbonits M 2008 The role of somatostatin analogues in the treatment of neuroendocrine tumours. Molecular and Cellular Endocrinology 286 238-250. (doi:10.1016/j.mce.2007.10.006)
50. Guillemin R 2005 Hypothalamic hormones a.k.a. hypothalamic releasing factors. Journal of Endocrinology 184 11-28. (doi:10.1677/joe.1.05883)
51. Gurevich VV & Gurevich EV 2006 The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacology & Therapeutics 110 465-502. (doi:10.1016/j.pharmthera.2005.09.008)
52. Gustafsson BI, Kidd M & Modlin IM 2008 Neuroendocrine tumors of the diffuse neuroendocrine system. Current Opinion in Oncology 20 1-12. (doi:10.1097/CCO.0b013e3282f1c595)
53. van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Lowenberg B &Lamberts SW 1994 Somatostatin and the immune and haematopoetic system; a review. European Journal of Clinical Investigation 24 91-99. (doi:10.1111/j.1365-2362.1994.tb00972.x)
54. van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ et al. 2005 The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clinical Endocrinology 63 176-184. (doi:10.1111/j.1365-2265.2005.02322.x)
55. Hofland LJ & Lamberts SW 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews 24 28-47. (doi:10.1210/er.2000-0001)
56. Hofland LJ, Visser-Wisselaar HA & Lamberts SW 1995 Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. Biochemical Pharmacology 50 287-297. (doi:10.1016/0006-2952(95)00066- 9)
57. Hofland LJ, Liu Q, Van Koetsveld PM, Zuijderwijk J, Van Der Ham F, De Krijger RR, Schonbrunn A & Lamberts SW 1999 Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. Journal of Clinical Endocrinology and Metabolism 84 775-780. (doi:10.1210/jc.84.2.775)
58. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW et al. 2005a The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology 152 645-654. (doi:10.1530/eje.1.01876)
59. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W & Lamberts SW 2005b Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. Journal of Endocrinological Investigation 28 36-42.
60. 2 receptors as molecular targets. Molecular and Cellular Endocrinology 326 89-98. (doi:10.1016/j.mce.2010.04.020)
61. Hofmann KP, Scheerer P, Hildebrand PW, Choe HW, Park JH, Heck M & Ernst OP 2009 A G protein-coupled receptor at work: the rhodopsin model. Trends in Biochemical Sciences 34 540-552. (doi:10.1016/j.tibs.2009.07.005)
62. Ishibashi M, Fujisawa M, Furue H, Maeda Y, Fukayama M & Yamaji T 1994 Inhibition of growth of human small cell lung cancer by bromocriptine. Cancer Research 54 3442-3446. (Pubitemid 24225964)
63. 2-receptor agonist and antagonist drugs on somatostatin binding, inhibition of adenylyl cyclase activity and accumulation of inositol 1,4,5-trisphosphate in the rat striatum. Brain Research. Molecular Brain Research 47 99-107. (doi:10.1016/S0169-328X(97) 00063-6)
64. Jacobs S & Schulz S 2008 Intracellular trafficking of somatostatin receptors. Molecular and Cellular Endocrinology 286 58-62. (doi:10.1016/j.mce. 2007.10.005)
65. Janson ET, Stridsberg M, Gobl A, Westlin JE & Oberg K 1998 Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Research 58 2375-2378. (Pubitemid 28252697)
66. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A & Culler MD 2005a Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. European Journal of Endocrinology 153 135-141. (doi:10.1530/eje.1.01950)
67. Jaquet P, Saveanu A & Barlier A 2005b New SRIF analogs in the control of human pituitary adenomas: perspectives. Journal of Endocrinological Investigation 28 14-18. (Pubitemid 46211834)
68. Kidd M, Modlin IM, Black JW, Boyce M & Culler M 2007a A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation. Regulatory Peptides 143 109-117. (doi:10.1016/j.regpep.2007.04.002)
69. Kidd M, Modlin IM, Pfragner R, Eick GN, Champaneria MC, Chan AK, Camp RL & Mane SM 2007b Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1. Cancer 109 2420-2431. (doi:10.1002/cncr.22725)
70. Kidd M, Drozdov I, Joseph R, Pfragner R, Culler M & Modlin I 2008 Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 113 690-700. (doi:10.1002/cncr.23700)
71. Kimura N, Pilichowska M, Date F, Kimura I & Schindler M 1999 Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clinical Cancer Research 5 3483-3487.
72. Koenig JA & Edwardson JM 1997 Endocytosis and recycling of G protein-coupled receptors. Trends in Pharmacological Sciences 18 276-287. (Pubitemid 27353245)
73. Kolby L, Bernhardt P, Johanson V, Wangberg B, Muth A, Jansson S, Forssell-Aronsson E, Nilsson O & Ahlman H 2006 Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Annals of the New York Academy of Sciences 1073 491-497. (doi:10.1196/annals.1353.051)
74. Korner M, Eltschinger V, Waser B, Schonbrunn A & Reubi JC 2005 Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. American Journal of Surgical Pathology 29 1642-1651. (doi:10.1097/01.pas.0000174013.14569.90)
75. Kosmidis PA 2004 Treatment of carcinoid of the lung. Current Opinion in Oncology 16 146-149. (doi:10.1097/00001622-200403000-00011)
76. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S & Seino Y 1994 Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. Journal of Clinical Investigation 93 1321-1325. (doi:10.1172/JCI117090)
77. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y & Arnold R 2002 Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 50 52-60. (doi:10.1136/gut.50.1.52)
78. Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY & Krenning EP 1993 In vivo somatostatin receptor imaging in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 76 1413-1417. (doi:10.1210/jc.76.6.1413)
79. Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C & Susini C 2004 Molecular signaling of somatostatin receptors. Annals of the New York Academy of Sciences 1014 121-131. (doi:10.1196/annals.1294.012)
80. Lamberts SW, Krenning EP & Reubi JC 1991 The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews 12 450-482. (doi:10.1210/edrv-12-4-450)
81. Lamberts SW, van der Lely AJ, de Herder WW & Hofland LJ 1996 Octreotide. New England Journal of Medicine 334 246-254. (doi:10.1056/ NEJM199601253340408)
82. Lee SP, O'Dowd BF & George SR 2003 Homo- and heterooligomerization of G protein-coupled receptors. Life Sciences 74 173-180. (doi:10.1016/j.lfs.2003. 09.028)
83. Lemmer K, Ahnert-Hilger G, Hopfner M, Hoegerle S, Faiss S, Grabowski P, Jockers-Scherubl M, Riecken EO, Zeitz M & Scherubl H 2002 Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sciences 71 667-678. (doi:10.1016/S0024-3205(02)01703-4)
84. Lesche S, Lehmann D, Nagel F, Schmid HA & Schulz S 2009 Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. Journal of Clinical Endocrinology and Metabolism 94 654-661. (doi:10.1210/jc.2008-1919)
85. Lichtenauer-Kaligis EG, Dalm VA, Oomen SP, Mooij DM, van Hagen PM, Lamberts SW & Hofland LJ 2004 Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. European Journal of Endocrinology 150 565-577. (doi:10.1530/eje.0.1500565)
86. Lugtenburg PJ, Krenning EP, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, van Putten WL & Lowenberg B 2001a Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: more extended disease identified. British Journal of Haematology 112 936-944. (doi:10.1046/j.1365-2141.2001.02583.x)
87. Lugtenburg PJ, Lowenberg B, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, van Putten WL & Krenning EP 2001b Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. Journal of Nuclear Medicine 42 222-229. (Pubitemid 32150512)
88. Martin-Iverson MT, Radke JM & Vincent SR 1986 The effects of cysteamine on dopamine-mediated behaviors: evidence for dopamine-somatostatin interactions in the striatum. Pharmacology, Biochemistry, and Behavior 24 1707-1714. (doi:10.1016/0091-3057(86)90509-5)
89. Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G & Colao A 1999 Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1 115-120. (doi:10.1023/A:1009932521242)
90. Mato E, Matias-Guiu X, Chico A, Webb SM, Cabezas R, Berna L & De Leiva A 1998 Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 83 2417-2420. (doi:10.1210/jc.83.7.2417)
91. McMullan DM & Wood DE 2003 Pulmonary carcinoid tumors. Seminars in Thoracic and Cardiovascular Surgery 15 289-300. (doi:10.1016/S1043-0679(03) 70009-4)
92. Missale C, Nash SR, Robinson SW, Jaber M & Caron MG 1998 Dopamine receptors: from structure to function. Physiological Reviews 78 189-225. (Pubitemid 28070979)
93. Modlin IM, Latich I, Kidd M, Zikusoka M & Eick G 2006 Therapeutic options for gastrointestinal carcinoids. Clinical Gastroenterology and Hepatology 4 526-547. (doi:10.1016/j.cgh.2005.12.008)
94. Moller LN, Stidsen CE, Hartmann B & Holst JJ 2003 Somatostatin receptors. Biochimica et Biophysica Acta 1616 1-84. (doi:10.1016/S0005-2736(03) 00235-9)
95. Mundschenk J, Unger N, Schulz S, Hollt V, Steinke R & Lehnert H 2003 Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. Journal of Clinical Endocrinology and Metabolism 88 5150-5157. (doi:10.1210/jc.2003-030262)
96. 2 dopamine receptor. Journal of Biological Chemistry 279 49533-49541. (doi:10.1074/jbc.M408319200)
97. 2 dopamine receptor. Journal of Biological Chemistry 284 15038-15051. (doi:10.1074/jbc.M900388200)
98. Oakley RH, Laporte SA, Holt JA, Caron MG & Barak LS 2000 Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. Journal of Biological Chemistry 275 17201-17210. (doi:10.1074/jbc.M910348199)
99. Oakley RH, Laporte SA, Holt JA, Barak LS & Caron MG 2001 Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis*. Journal of Biological Chemistry 276 19452-19460. (doi:10.1074/jbc.M101450200)
100. Oberg K 2002 Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Current Opinion in Oncology 14 38-45. (doi:10.1097/00001622-200201000-00008)
101. Oberg KE 2010 Gastrointestinal neuroendocrine tumors. Annals of Oncology 21 (Suppl 7) vii72-vii80. (doi:10.1093/annonc/mdq290)
102. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH & Valimaki M 2004a Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncologica 43 617-625. (doi:10.1080/02841860410018575)
103. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH & Valimaki M 2004b Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncologica 43 626-636. (doi:10.1080/02841860410018584)
104. Ono K, Suzuki T, Miki Y, Taniyama Y, Nakamura Y, Noda Y, Watanabe M & Sasano H 2007 Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Research 27 2231-2239. (Pubitemid 47228058)
105. O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, Hyrdel R, Nikou G, Krenning E, Vullierme MP et al. 2006a Rare functioning pancreatic endocrine tumors. Neuroendocrinology 84 189-195. (doi:10.1159/ 000098011)
106. O'Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, Ruszniewski P & Barlier A 2006b The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. European Journal of Endocrinology 155 849-857. (doi:10.1530/eje.1.02307)
107. Pacini F, Basolo F, Elisei R, Fugazzola L, Cola A & Pinchera A 1991 Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. American Journal of Clinical Pathology 95 300-308.
108. Panetta R & Patel YC 1995 Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sciences 56 333-342. (doi:10.1016/0024-3205(94)00956-2)
109. Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M & Bussolati G 2000 Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagnostic Molecular Pathology 9 47-57. (doi:10.1097/00019606-200003000-00008)
110. Papotti M, Croce S, Bello M, Bongiovanni M, Allia E, Schindler M & Bussolati G 2001a Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Archiv: an International Journal of Pathology 439 787-797. (Pubitemid 33141324)
111. Papotti M, Kumar U, Volante M, Pecchioni C & Patel YC 2001b Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clinical Endocrinology 54 641-649. (doi:10.1046/j.1365-2265.2001.01175.x)
112. Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL & Bussolati G 2002 Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Archiv: an International Journal of Pathology 440 461-475. (doi:10.1007/s00428-002-0609-x)
113. Pasquali D, Rossi V, Conzo G, Pannone G, Bufo P, DeBellis A, Renzullo A, Bellastella G, Colao A, Vallone G et al. 2008 Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. Journal of Molecular Endocrinology 40 263-271. (Pubitemid 351865034)
114. Patel YC 1997 Molecular pharmacology of somatostatin receptor subtypes. Journal of Endocrinological Investigation 20 348-367. (Pubitemid 27410043)
115. Patel YC 1999 Somatostatin and its receptor family. Frontiers in Neuroendocrinology 20 157-198. (doi:10.1006/frne.1999.0183)
116. Patel RC, Lange DC & Patel YC 2002 Photobleaching fluorescence resonance energy transfer reveals ligand-induced oligomer formation of human somatostatin receptor subtypes. Methods 27 340-348. (doi:10.1016/S1046-2023(02) 00092-0)
117. Pathak RD, Tran TH & Burshell AL 2004 A case of dopamine agonists inhibiting pancreatic polypeptide secretion from an islet cell tumor. Journal of Clinical Endocrinology and Metabolism 89 581-584. (doi:10.1210/jc.2003-031039)
118. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, Hollt V & Schulz S 2001 Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). Journal of Biological Chemistry 276 14027-14036.
119. Pippig S, Andexinger S & Lohse MJ 1995 Sequestration and recycling of beta 2-adrenergic receptors permit receptor resensitization. Molecular Pharmacology 47 666-676.
120. Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, van Koetsveld PM, Barreca A, De Caro ML, Lombardi G et al. 2004a Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. Journal of Clinical Endocrinology and Metabolism 89 4493-4502. (doi:10.1210/jc.2003-031746)
121. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ et al. 2004b Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 89 2452-2462. (doi:10.1210/jc.2003-030837)
122. Pivonello R, Ferone D, Lamberts SW & Colao A 2005 Cabergoline plus lanreotide for ectopic Cushing's syndrome. New England Journal of Medicine 352 2457-2458. (doi:10.1056/NEJM200506093522322)
123. Pivonello R, Ferone D, de Herder WW, Faggiano A, Bodei L, de Krijger RR, Lombardi G, Colao A, Lamberts SW & Hofland LJ 2007a Dopamine receptor expression and function in corticotroph ectopic tumors. Journal of Clinical Endocrinology and Metabolism 92 65-69. (doi:10.1210/jc.2006-0728)
124. Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW & Hofland LJ 2007b Novel insights in dopamine receptor physiology. European Journal of Endocrinology 156 (Suppl 1) S13-S21. (doi:10.1530/eje.1.02353)
125. Pivonello R, Ceresola E, Albertelli M, Faggiano A, Torre G, De Martino MC, Culler M, Lombardi G, Minuto F, Colao A et al. 2008 Expression of somatostatin and dopamine receptors and effect of chimeric somatostatin-dopamine molecules on cell proliferation in pancreatic neuroendocrine tumors. Proceedings of the European Neuroendocrine Tumour Society, 5th Annual Conference, Paris, France. Poll F, Lehmann D, Illing S, Ginj M, Jacobs S, Lupp A, Stumm R & Schulz S 2010 Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Molecular Endocrinology 24 436-446. (doi:10.1210/me.2009-0315)
126. 2 receptor gene expression and binding sites in adrenal medulla and pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 79 56-61. (doi:10.1210/jc.79.1.56)
127. Reisine T & Bell GI 1995 Molecular biology of somatostatin receptors. Endocrine Reviews 16 427-442.
128. Reisinger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, Kettner B, Otto HJ, Schmidt S & Munz DL 1998 Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. Journal of Nuclear Medicine 39 224-227. (Pubitemid 28114504)
129. Reith P, Monnot EA & Bathija PJ 1987 Prolonged suppression of a corticotropin-producing bronchial carcinoid by oral bromocriptine. Archives of Internal Medicine 147 989-991. (doi:10.1001/archinte.147.5.989)
130. Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD & Melmed S 2003a Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. Journal of Clinical Endocrinology and Metabolism 88 5414-5421. (doi:10.1210/jc.2003-030302)
131. Ren SG, Taylor J, Dong J, Yu R, Culler MD & Melmed S 2003b Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. Journal of Clinical Endocrinology and Metabolism 88 4239-4245. (doi:10.1210/jc.2003-030303)
132. Reubi JC 2003 Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Reviews 24 389-427. (doi:10.1210/er.2002-0007)
133. Reubi JC 2004 Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80 (Suppl 1) 51-56. (doi:10.1159/000080742)
134. Reubi JC 2007 Peptide receptor expression in GEP-NET. Virchows Archiv: an International Journal of Pathology 451 (Suppl 1) S47-S50. (Pubitemid 47283376)
135. Reubi JC & Waser B 2003 Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging 30 781-793. (doi:10.1007/s00259-003-1184-3)
136. Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JG & Lamberts SW 1987 Somatostatin receptors in human endocrine tumors. Cancer Research 47 551-558. (Pubitemid 17009625)
137. Reubi JC, Krenning E, Lamberts SW & Kvols L 1992a In vitro detection of somatostatin receptors in human tumors. Metabolism 41 104-110. (doi:10.1016/0026-0495(92)90042-9)
138. Reubi JC, Laissue J, Krenning E & Lamberts SW 1992b Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. Journal of Steroid Biochemistry and Molecular Biology 43 27-35. (doi:10.1016/0960-0760(92)90184-K)
139. Reubi JC, Waser B, Khosla S, Kvols L, Goellner JR, Krenning E & Lamberts S 1992c In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. Journal of Clinical Endocrinology and Metabolism 74 1082-1089. (doi:10.1210/jc.74.5.1082)
140. Reubi JC, Waser B, van Hagen M, Lamberts SW, Krenning EP, Gebbers JO & Laissue JA 1992d In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. International Journal of Cancer 50 895-900. (doi:10.1002/ijc.2910500613)
141. Reubi JC, Laissue J, Waser B, Horisberger U & Schaer JC 1994a Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Annals of the New York Academy of Sciences 733 122-137. (doi:10.1111/j.1749-6632.1994.tb17262.x)
142. Reubi JC, Schaer JC, Waser B & Mengod G 1994b Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Research 54 3455-3459. (Pubitemid 24225966)
143. Reubi JC, Schaer JC, Laissue JA & Waser B 1996 Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 45 39-41. (doi:10.1016/S0026-0495(96)90077-3)
144. Reubi JC, Horisberger U, Kappeler A & Laissue JA 1998a Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. Blood 92 191-197. (Pubitemid 28303192)
145. 2A in human tumors. American Journal of Pathology 153 233-245. (doi:10.1016/S0002-9440(10)65564-2)
146. 2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. Journal of Clinical Endocrinology and Metabolism 85 3882-3891. (doi:10.1210/jc.85.10.3882)
147. Reubi JC, Waser B, Cescato R, Gloor B, Stettler C & Christ E 2010 Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. Journal of Clinical Endocrinology and Metabolism 95 2343-2350. (doi:10.1210/jc.2009-2487)
148. Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G, Roncella M, Mosca F & Conte PF 2000 Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. American Journal of Clinical Oncology 23 412-415. (Pubitemid 32429157)
149. Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G & Papotti M 2010 Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Annals of Oncology 21 548-555. (doi:10.1093/annonc/mdp334)
150. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/JCO.2009.22.8510)
151. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC 2000a Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288 154-157. (doi:10.1126/science.288. 5463.154)
152. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC & Patel YC 2000b Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. Journal of Biological Chemistry 275 7862-7869. (doi:10.1074/jbc.275.11.7862)
153. Ruscica M, Arvigo M, Gatto F, Dozio E, Feltrin D, Culler MD, Minuto F, Motta M, Ferone D & Magni P 2010 Regulation of prostate cancer cell proliferation by somatostatin receptor activation. Molecular and Cellular Endocrinology 315 254-262. (doi:10.1016/j.mce.2009.11.006)
154. de Sa SV, Correa-Giannella ML, Machado MC, de Souza JJ, Pereira MA, Patzina RA, Siqueira SA & Giannella-Neto D 2006 Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocrine-Related Cancer 13 69-78. (doi:10.1677/erc.1.00962)
155. Saveanu A & Jaquet P 2009 Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Reviews in Endocrine & Metabolic Disorders 10 83-90. (doi:10.1007/s11154-008-9086-0)
156. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A & Jaquet P 2001 Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 86 140-145. (doi:10.1210/jc.86.1.140)
157. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD & Jaquet P 2006 Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 83 258-263. (doi:10.1159/000095536)
158. 2 receptors in pituitary adenomas. Molecular and Cellular Endocrinology 286 206-213. (doi:10.1016/j.mce. 2007.12.008)
159. Schally AV 1988 Oncological applications of somatostatin analogues. Cancer Research 48 6977-6985. (Pubitemid 19013968)
160. Schmid HA 2008 Pasireotide (SOM230): development, mechanism of action and potential applications. Molecular and Cellular Endocrinology 286 69-74. (doi:10.1016/j.mce.2007.09.006)
161. Schmid HA & Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80 (Suppl 1) 47-50. (doi:10.1159/000080741)
162. Schonbrunn A 2008 Selective agonism in somatostatin receptor signaling and regulation. Molecular and Cellular Endocrinology 286 35-39. (doi:10.1016/j.mce.2007.09.009)
163. Sestini R, Orlando C, Peri A, Tricarico C, Pazzagli M, Serio M, Pagani A, Bussolati G, Granchi S & Maggi M 1996 Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clinical Cancer Research 2 1757-1765. (Pubitemid 26356362)
164. Srirajaskanthan R, Watkins J, Marelli L, Khan K & Caplin ME 2009 Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology 89 308-314. (doi:10.1159/000179899)
165. 2 receptor gene expression in human adenohypophysial adenomas. Endocrine 14 329-336. (doi:10.1385/ENDO:14:3:329)
166. Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP et al. 2007 Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. European Journal of Endocrinology 156 65-74. (doi:10.1530/eje.1.02313)
167. Tsao PI & von Zastrow M 2000 Type-specific sorting of G protein-coupled receptors after endocytosis. Journal of Biological Chemistry 275 11130-11140. (doi:10.1074/jbc.275.15.11130)
168. Tulipano G & Schulz S 2007 Novel insights in somatostatin receptor physiology. European Journal of Endocrinology 156 (Suppl 1) S3-S11. (doi:10.1530/eje.1.02354)
169. 5 in various adrenal tumors and normal adrenal gland. Hormone and Metabolic Research 37 722-728. (doi:10.1055/s-2005- 921092)
170. Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Schmid KW, Mann K & Petersenn S 2004 Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4, and 5 in various adrenal tumors. Endocrine Research 30 931-934. (doi:10.1081/ERC-200044161)
171. Vikic-Topic S, Raisch KP, Kvols LK & Vuk-Pavlovic S 1995 Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. Journal of Clinical Endocrinology and Metabolism 80 2974-2979. (doi:10.1210/jc.80.10.2974)
172. Volante M, Rosas R, Allia E, Granata R, Baragli A, Muccioli G & Papotti M 2008 Somatostatin, cortistatin and their receptors in tumours. Molecular and Cellular Endocrinology 286 219-229. (doi:10.1016/j.mce.2007.12. 002)
173. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D & Bruns C 2003 Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Reviews. Drug Discovery 2 999-1017. (doi:10.1038/nrd1255)
174. 2 and D4 receptor mRNA in the adrenal gland, aldosterone-producing adenoma, and pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 86 4460-4467. (doi:10.1210/jc.86.9.4460)
175. Wynick D & Bloom SR 1991 Clinical review 23: the use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 73 1-3. (doi:10.1210/jcem-73-1-1)
176. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. 2008 One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. Journal of Clinical Oncology 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
177. Yu SS, Lefkowitz RJ & Hausdorff WP 1993 Beta-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. Journal of Biological Chemistry 268 337-341. (Pubitemid 23021326)
178. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD & degli Uberti EC 2005 Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. Journal of Molecular Endocrinology 35 333-341.
179. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C, Margutti A, Bondanelli M, Pansini GC, Pelizzo MR et al. 2006 Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. Journal of Clinical Endocrinology and Metabolism 91 2218-2224. (doi:10.1210/jc.2006-0334)